SITC Advances in Cancer Immunotherapy™ Online Courses


ACI 2021-2022 Online Interactive Courses & Accredited Webinars: The 2021-2022 ACI webinars are designed for those who were not able to attend the live program, but still want to view the content, Q&A and panel discussions and receive credit for their attendance. As an added benefit, two additional interactive CE- courses (Introduction to Immunotherapy and Mechanisms of IrAEs) are offered to provide a thorough and interactive dive into these foundational concepts at no cost.

ACI 2020-21 Online Interactive Courses: The 2020-2021 ACI courses offer an interactive educational experience, approximately an hour in length, for a more comprehensive dive into each topic. Credit is available for each course.

ACI 2021-2022 Online Interactive Courses & Accredited Webinars
Collapse Advances in Cancer Immunotherapy™: A Focus on Immune Checkpoint Inhibitors

Published 5/20/2022

 

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Immune Checkpoint Inhibitors. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

 

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

  PIM_logo.pngsitc_log_color.png

 

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

 

Credit Available: May 20, 2022 - May 20, 2023

 

Estimated time to complete activity: 3.75 hours

 

Faculty: 

Marina Chiara Garassino, MD - The University of Chicago

Natalie Vokes, MD - The University of Texas MD Anderson Cancer Center

Jarushka Naidoo, MBBCH, MHS - Beaumont RCSI Cancer Centre, Dublin

Diane Tseng, MD, PhD - University of Washington School of Medicine, Fred Hutchinson Cancer Research Center

Bonnie Bermas, MD - UT Southwestern Medical Center

Vickie Shannon, MD - The University of Texas MD Anderson Cancer Center

Sadia Ali, MD - UT Southwestern Medical Center

Nikhil I. Khushalani, MD - Moffitt Cancer Center

 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Describe the mechanisms of immune checkpoint inhibitors.
  • Summarize recent updates in the use of immune checkpoint inhibitors clinically.
  • Outline common toxicities with immune checkpoint inhibitors and their management.

 

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

 

Joint Accreditation Statement

Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CME-MOC_badge.jpg

 

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

 

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-240-H01-P)

Type of Activity: Knowledge

 

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

 


Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Original Course Date: April 23, 2022

Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Immune Checkpoint Inhibitors
    Collapse Advances in Cancer Immunotherapy™: Mechanisms of Immune-Related Adverse Events

    Published May 23, 2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This interactive course provides an overview of the mechanisms of immune-related adverse events (irAEs) that may be caused by implementing cancer immunotherapy.  This module walks the learner through the various mechanisms of irAEs, as well as differentiating early and late irAEs which may be distinguished by distinct mechanisms.  Learners will also have the opportunity to apply the knowledge gained in this module through two case studies.  

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: May 23, 2022 - May 23, 2023

     

    Estimated time to complete activity: 15 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify the various mechanisms of irAEs as well as the types of irAEs that may result.
    • Describe various irAEs as well as treatment for severe irAEs.
    • Differentiate central vs. peripheral tolerance of irAEs.

     

    Faculty
    Pradnya Patil, MD, FACP

    Associate Staff / Department of Hematology-Oncology

    Cleveland Clinic, Cleveland

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Pradnya Patil, MD, FACP - Nothing to disclose.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period May 23, 2022 through May 23, 2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of  0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. 

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-279-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: March 16, 2022

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: Mechanisms of Immune-Related Adverse Events
    Collapse Advances in Cancer Immunotherapy™: A Focus on Skin Cancers

    Published 3/24/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Skin Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: March 24, 2022 - March 24, 2023

     

    Estimated time to complete activity: 3.75 hours

     

    Faculty:

    Allison Betof Warner, MD, PhD - Memoral Sloan Kettering Cancer Center

    Isabella C. Glitza, MD, PhD - The University of Texas MD Anderson Cancer Center

    Janice Mehnert, MD - NYU Langone Health

    Michael K. Wong - MD, PhD - The University of Texas MD Anderson Cancer Center

    Ryan J. Sullivan, MD - Harvard Medical School, Massachusetts General Hospital

    Omid Hamid, MD - The Angeles Clinic and Research Institute

    Jarushka Naidoo, MBBCH, MHS - Beaumont RCSI Cancer Centre Dublin

    Kathy Madden, NP, RN, MSN, FNP-BC, AOCNP, APHN - NYU Langone Perlmutter Cancer Center

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify the cancer immunotherapy approaches in use for the treatment of skin cancers.
    • Summarize recent updates in cancer immunotherapy for skin cancers, including emerging toxicities and managment.
    • Implement cancer immunotherapy for skin cancer into clinical pratice appropriately.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number  - JA4008162-9999-22-130-H01-P

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: February 24, 2022

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Skin Cancers
    Collapse Advances in Cancer Immunotherapy™: A Focus on Intratumoral Therapies, Vaccines, and Cytokines

    Published 2/24/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Intratumoral Therapies, Vaccines, and Cytokines. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: February 24, 2022 - February 24, 2023

     

    Estimated time to complete activity: 3.75 hours

     

    Faculty: 

    Diwakar Davar, MMBBS, MSc - UPMC Hillman Cancer Center

    Patrick Ott, MD, PhD - Dana Farber Cancer Institute

    Adi Diab, MD - The University of Texas MD Anderson Cancer Center

    Harriet Kluger, MD - Yale School of Medicine

    Matthew J. Frigault, MD, MSc - Massachusetts General Hospital

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the mechanisms of intratumoral therapies, vaccines, and cytokines.
    • Summarize recent updates in the use of intratumoral therapies, vaccines, and cytokines clinically.
    • Outline common toxicities with intratumoral therapies, vaccines, and cytokines, and their management.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-073-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: January 27, 2022

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Intratumoral Therapies, Vaccines, and Cytokines
    Collapse Advances in Cancer Immunotherapy™: A Focus on Head and Neck Cancers

    Published 2/9/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Head and Neck Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: February 9, 2022 - February 9, 2023

     

    Estimated time to complete activity: 3.75 hours

     

    Faculty: 

    Jessica R. Bauman, MD - Fox Chase Cancer Center

    Jessica L. Geiger, MD - Cleveland Clinic Cancer Center

    Dan P. Zandberg, MD - UPMC Hillman Cancer Center

    Tanguy Seiwert, MD - Johns Hopkins Medicine

    Trisha Wise-Draper, MD, PhD - University of Cincinnati Cancer Center

    Ranee Mehra, MD - University of Maryland

    Ravindra Uppaluri, MD, PhD - Dana Farber Cancer Institute and Brigham and Women's Hospital

    Sana Karam, MD, PhD - University of Colorado

    Aarti Bhatia, MD - Yale School of Medicine

    Sid Sheth, MD - UNC School of Medicine

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify the cancer immunotherapy approaches in the use for the treatment of head and neck cancers.
    • Summarize recent updates in cancer immunotherapy for head and neck cancers as well as toxicity management for key disease states.
    • Implement cancer immunotherapy for head and neck cancers into clinical practice appropriately.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-052-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: January 12, 2022

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Head and Neck Cancers
    Collapse Advances in Cancer Immunotherapy™: Introduction to Immunotherapy

    Published 3/15/2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This interactive course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy. 

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: March 15, 2022 - March 15, 2023

     

    Estimated time to complete activity: 30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for cancer.
    • Identify the various types and appropriate use of cancer immunotherapy.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Christian Capitini, MD

    Associate Professor of Pediatrics Hematology/Oncology

    University of Wisconsin - Madison

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Christian Capitini, MD - Consulting Fees: Nektar Therapeutics; Novartis; Elephas Bio

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 3/15/2022 through 03/15/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of  0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.3 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5  contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-110-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: December 22, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: Introduction to Immunotherapy
    Collapse Advances in Cancer Immunotherapy™: A Focus on Cellular Therapies and T Cell Engagers

    Published 2/9/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Cell Therapies and T Cell Engagers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: February 9, 2022 - February 9, 2023

     

    Estimated time to complete activity: 3.75 hours

     

    Faculty: 

    Loretta Nastoupil, MD - The University of Texas MD Anderson Cancer Center

    Tycel J. Phillips, MD - University of Michigan Health

    Krina K. Patel, MD, MSc - The University of Texas MD Anderson Cancer Center

    Hans Lee, MD - The University of Texas MD Anderson Cancer Center

    Joanna C. Yang, MD, MPH - Washington University

    Chelsea C. Pinnix, MD, PhD - The University of Texas MD Anderson Cancer Center

    Yi Lin, MD, PhD - Mayo Clinic

    Tania Jain, MBBS - Johns Hopkins University

    Zainab Shahid, MD, FACP - University of North Carolina at Chapel Hill

    Surbhi Sidana, MD - Stanford University

     

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the mechanisms of cell therapies and T cell engagers.
    • Summarize recent updates in the use of cell therapies and T cell engagers clinically.
    • Outline common toxicities with cell therapies and T cell engagers and their management
    • Identify unique institutional resources required for the appropriate use of cell therapies.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.4 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-045-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: December 18, 2021

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Cellular Therapies and T Cell Engagers
    Collapse Advances in Cancer Immunotherapy™: A Focus on Gynecologic Cancers

    Published 2/9/22

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Gynecologic Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: February 9, 2022 - February 9, 2023

     

    Estimated time to complete activity: 3.75 hours

     

    Faculty: 

    Amy Bregar, MD - Massachusetts General Hospital

    Roisin O'Cearbhaill, MD - Memorial Sloan Ketting Cancer Center

    Mary L. Disis, MD, FACP - Univerisity of Washington

    Kerry Reynolds, MD - Massachusetts General Hospital

    Shannon Westin, MD - MD Anderson Cancer Center

    Emese Zsiros, MD, PhD - Rosewell Park Cancer Institute

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify the cancer immunotherapy approaches in use for the treatment of gynecologic cancers.
    • Summarize recent updates in cancer immunotherapy for gynecologic cancers including emerging toxicities and management.
    • Implement cancer immunotherapy for gynecologic cancer into clinical practice appropriately.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of  3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-104-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: December 14, 2021

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Gynecologic Cancers
    Collapse Advances in Cancer Immunotherapy™: A Focus on Biomarkers

    Published 4/21/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Biomarkers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: April 21, 2022 - April 21, 2023

     

    Estimated time to complete activity: 3.75 hours

     

    Faculty: 

    Allen Gown, MD - University of British Columbia

    Andrew Coveler, MD - University of Washington / Fred Hutchinson Cancer Research Center

    Eric Konnick, MD, MS - University of Washington

    Nora Disis, MD, FACP - University of Washington

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Discuss biomarkers in clinical use with approved cancer immunotherapies.
    • Summarize recent updates in the use of biomarkers for cancer immunotherapies.
    • Implement th euse of biomarkers to select appropriate treatments for patients with cancer.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-236-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: November 03, 2021

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Biomarkers
    Collapse Advances in Cancer Immunotherapy™: A Focus on Toxicity Management

    Published 5/26/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Toxicity Management. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available:  May 26, 2022 - May 26, 2023

     

    Estimated time to complete activity: 4.0 hours

     

    Faculty:

    Noha Abdel-Wahab, MD, PhD - The University of Texas MD Anderson Cancer Center

    Adi Diab, MD - The University of Texas MD Anderson Cancer Center

    Van Anh Trinh, PharmD - The University of Texas MD Anderson Cancer Center

    Sumit Subudhi, MD, PhD - The University of Texas MD Anderson Cancer Center

    Mehmet Altan, MD - The University of Texas MD Anderson Cancer Center

    Nicolas L. Palaskas, MD - The University of Texas MD Anderson Cancer Center

    Yinghong Wang, MD, PhD, MSc - The University of Texas MD Anderson Cancer Center

    Maen Abdelrahim, MD, PhD, PharmD - Houston Methodist

    Jennifer A. Wargo, MD, MMSc - The University of Texas MD Anderson Cancer Center

    Michelle Rohlfs, APRN, FNP-BC, AOCNP - The University of Texas MD Anderson Cancer Center

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify appropriate clinical management of common immune-related adverse events resulting from cancer immunotherapy treatments, including immune checkpoint inhibitors and cell therapies.
    • Outline the best practices for multidisciplinary management of patients receiving cancer immunotherapy treatment.
    • Describe management approaches for difficult or refractory immune-related adverse events.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 4.0 contact hours. Designated for 2.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 4.0 contact hours (0.4 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-241-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: November 03, 2021

    Approved Credit:
  • ACPE: 4.00 hours Contact Hour
  • ANCC: 4.00 hours Contact Hour
  • ACCME (MD/DO): 4.00 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 4.00 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 4.00 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Toxicity Management
    Collapse Advances in Cancer Immunotherapy™: A Focus on Breast Cancers

    Published 4/6/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Breast Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: April 6, 2022 - April 6, 2023

     

    Estimated time to complete activity: 3.75 hours

     

    Faculty: 

    Leisha Emens, MD, PhD - University of Pittsburgh

    Daniel Stover, MD - The Ohio State University

    Ashley Cimino-Mathews, MD - Johns Hopkins University

    Laura Kennedy, MD, PhD - Vanderbilt University

    Sagar Sardesai, MBBS - The Ohio State University

    Margaret Gatti-Mays, MD, MPH – Ohio State University Comprehensive Cancer Center

    Melissa Wilson, PA-C, MPAS - University of Pittsburgh

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify the cancer immunotherapy approaches in use for the treatment of breast cancers.
    • Summarize recent updates in cancer immunotherapy for breast cancers including emerging toxicities and management.
    • Implement cancer immunotherapy for breast cancer into clinical practice appropriately.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 2.0 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-184-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: November 03, 2021

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Breast Cancers
    Collapse Advances in Cancer Immunotherapy™: A Focus on Hematologic Malignancies

    Published 3/2/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Hematologic Malignancies. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: March 2, 2022 - March 2, 2023

     

    Estimated time to complete activity: 3.75hours

     

    Faculty: 

    Nina Shah, MD - University of California San Francisco

    Surbhi Sidana, MD - Stanford University

    Aaron Logan, MD, PhD - University of California San Francisco

    Naval Daver, MD - The University of Texas MD Anderson Cancer Center

    Michael Spinner, MD - Stanford University

    Charalambos (Babis) Andreadis, MD, MSCE - University of California San Francisco

    Samantha Shenoy, NP - UCSF Medical Center

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify the cancer immunotherapy approaches in use for the treatment of hematologic malignancies.
    • Summarize recent updates in cancer immunotherapy for hematologic malignancies, including emerging toxicities and management
    • Implement cancer immunotherapy for hematologic malignancies into clinical practice appropriately.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.75 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-078-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: November 03, 2021

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Hematologic Malignancies
    Collapse Advances in Cancer Immunotherapy™: A Focus on Lung Cancers

    Published 5/3/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Lung Cancer. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: May 3, 2022 - May 3, 2023

     

    Estimated time to complete activity: 3.75 hours

     

    Faculty: 

    Anne Chiang, MD, PhD -- Yale School of Medicine

    Marianne Davies, NP, DNP, MSN, BSN --Yale School of Nursing

    Roy S. Herbst, MD, PhD -- Yale Cancer Center, Yale School of Medicine, Smilow Cancer Hospital

    Hossein Borghaei, DO, MS -- Fox Chase Cancer Center

    Mark Awad, MD, PhD -- Dana-Farber Cancer Institute

    Sarah Goldberg, MD, MPH -- Yale School of Medicine

    Henry S. Park, MD, MPH -- Yale School of Medicine

    Scott N. Gettinger, MD -- Yale School of Medicine

     

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify cancer immunotherapy approaches in use for the treatment of lung cancers.
    • Summarize recent updates in cancer immunotherapy for lunch cancers including emerging toxicities and management.
    • Implement cancer immunotherapy for lung cancer into clinical practice appropriately.
    • Describe the use of biomarkers to select appropriate cancer immunotherapies for lung cancer patients.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-239-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: November 03, 2021

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Lung Cancers
    Collapse Advances in Cancer Immunotherapy™: A Focus on Monoclonal Antibodies and Antibody-drug Conjugates

    Published 3/10/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Monoclonal Antibodies and Antibody-Drug Conjugates. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: March 10, 2022 - March 10, 2023

     

    Estimated time to complete activity: 3.75 hours

     

    Faculty: 

    Komal Jhaveri, MD, FACP - Memorial Sloan Kettering Cancer Center

    Nina Shah, MD - University of California San Francisco

    David Ilson, MD, PhD - Memorial Sloan Kettering Cancer Center

    Daniel Petrylak, MD - Yale School of Medicine

    Patrick Brown, MD - Johns Hopkins University

    Aditya Bardia, MD, MPH - Massachusetts General Hospital

    Christian M. Captini, MD - University of Wisconsin-Madison

    Hope Rugo, MD - University of California San Francisco Comprehensive Care Center
     

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the mechanisms of monoclonal antibodies and antibody-drug conjugates.
    • Summarize recent updates in the use of monoclonal antibodies and antibody-drug conjugates clinically.
    • Outline common toxicities with monoclonal antibodies and antibody-drug conjugates and their management.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.2 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-079-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: November 03, 2021

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Monoclonal Antibodies and Antibody-drug Conjugates
    Collapse Advances in Cancer Immunotherapy™: A Focus on Gastrointestinal Cancers

    Published 2/9/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Gastrointestinal Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: February 9, 2022 - February 9, 2023

     

    Estimated time to complete activity: 3.25 hours

     

    Faculty: 

    Ghassan K. Abou-Alfa, MD, MBA - Memorial Sloan Kettering Cancer Center

    Arndt Vogel, MD - Medizinische Hochschule, Hannover, Germany

    James J. Harding, MD - Memorial Sloan Kettering Cancer Center

    Stephen L. Chan, MBBS, FRCP -The Chinese University of Hong Kong

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify the cancer immunotherapy approaches in use for the treatment of gastrointestinal cancers.
    • Summarize recent updates in cancer immunotherapy for gastrointestinal cancers including emerging toxicities and management.
    • Implement cancer immunotherapy for gastrointestinal cancer into clinical practice appropriately.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.25 contact hours. Designated for 1.0 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.25 contact hours (0.325 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-006-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: November 03, 2021

    Approved Credit:
  • ACPE: 3.25 hours Contact Hour
  • ANCC: 3.25 hours Contact Hour
  • ACCME (MD/DO): 3.25 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.25 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Gastrointestinal Cancers
    Collapse Advances in Cancer Immunotherapy™: A Focus on MSI-High and TMB-High Cancers

    Published 2/9/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on MSI-High and TMB-High Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: February 9, 2022 - February 9, 2023

     

    Estimated time to complete activity:  3.75 hours

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify the cancer immunotherapy approaches in use for the treatment of MSI-H/TMB-H cancers.
    • Summarize recent updates in cancer immunotherapy for MSI-H/TMB-H cancers and toxicity management for key disease states.
    • Implement cancer immunotherapy for MSI-H/TMB-H cancer into clinical practice appropriately.
    • Describe the rationale for the use of cancer immunotherapy in MSI-H/TMB-H cancers.

     

    Faculty

    Young Kwang Chae, MD, MPH, MBA - Northwestern University

    Daniel McGrail, PhD - The University of Texas MD Anderson Cancer Care Center

    Zsofia Stadler, MD - Memorial Sloamn Kettering Cancer Center

    John Strickler, MD - Duke University Medical Center

    Nicholas DeVito, MD - Duke University Hospital

    Funda Meric-Bernstam, MD - The University of Texas MD Anderson Cancer Care Center

    Neil Segal, MD, PhD - Memorial Sloamn Kettering Cancer Center

    Mohamed Salem, MD - Atrium Health

    Theresa Brown, PharmD, BCOP - Duke University Hospital

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.0 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-008-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: November 03, 2021

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on MSI-High and TMB-High Cancers
    Collapse Advances in Cancer Immunotherapy™: A Focus on Genitourinary Cancers

    Published 2/9/2022

     

    Course Description

    This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Genitourinary Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    Funders Statement

    The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

     

    Credit Available: February 9, 2022 - February 9, 2023

     

    Estimated time to complete activity: 3.75 hours

     

    Faculty: 

    Jessica Clement, MD - Hartford Healthcare

    Alexandra Drakaki, MD, PhD - UCLA

    David F. McDermott, MD - Beth israel Deconess Medical Center

    Tanya B. Dorff, MD - City of Hope

    Jeannie Hoffman-Censits, MD - Johns Hopkins

    Lisa Holle, PharmD, BCOP, FHOPA, FISOPP - UConn School of Pharmacy

    Lidia P. Lopez, AGPCNP-BC - UCLA

    Thomas Powles, MBBS, MD MRCP - Queen Mary University of London

    Tracy Rose, MD, MPH - University of North Carolina at Chapel Hill

    Virginia Seery, MSN, RN, AMP-BC, AOCNP - Beth Israel Deconess Medical Center

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify the cancer immunotherapy approaches in use for the treatment of genitourinary cancers.
    • Summarize recent updates in cancer immunotherapy for genitourinary cancers including emerging toxicities and management.
    • Implement cancer immunotherapy for genitourinary cancer into clinical practice appropriately.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.0 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-102-H01-P)

    Type of Activity: Knowledge

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: October 27, 2021

    Approved Credit:
  • ACPE: 3.75 hours Contact Hour
  • ANCC: 3.75 hours Contact Hour
  • ACCME (MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 3.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 3.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™: A Focus on Genitourinary Cancers
    ACI 2020-21 Online Interactive Courses
    Collapse Basic Principles of Cancer Immunotherapy

    Published: March 1, 2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Basic Principles will walk the learner through the biological foundations of immunotherapy, types of immunotherapies, illustrate how biomarkers play a major role in immunotherapy, as well as cover the patient response to immunotherapy and subsequent physician assessment.  

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  March 1, 2022 - March 1, 2023

     

    Estimated time to complete activity:  45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify key biological concepts of immunotherapy
    • Describe the various types of immunotherapy
    • Describe how biomakers play a key role in immunotherapy
    • Describe how to assess the patient response to immunotherapy

     

    Faculty
    Stefani Spranger, PhD

    Assistant Professor of Biology

    The Koch Institue for Integrative Cancer Research, Massachusetts Institue of Technology

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Stefani Spranger, PhD: Consulting Fees: Arcus, Tango, Takeda, Ribon, Merck, Dragonfly.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-081-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Basic Principles of Cancer Immunotherapy
    Collapse Immunotherapy for the Treatment of Skin Cancers

    Published 04/25/2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Skin Cancers, provides an overview of immunotherapy treatment for various forms of skin cancer. Multiple clinical trials are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for skin cancer.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  April 25, 2022 - April 25, 2023

     

    Estimated time to complete activity:  45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for skin cancer.
    • Identify FDA-approved immunotherapy treatments for skin cancer.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Shailender Bhatia, MD

    Associate Professor of Medical Oncology

    University of Washington

    Fred Hutchison Cancer Research Center, Seattle, WA

     

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Shailender Bhatia, MD: Consulting Fees: Genentech, BMS, EMD-Serono, Sanofi-Genzyme, Exicure.   Contracted research: BMS, EMD-Serono, Immune Design, Merck, Novartis, Oncosec, Nantkwest, Exicure, Nektar, CheckMate, Xencor, Trisalus.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 04/25/2022 through 04/25/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.4 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-235-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Skin Cancers
    Collapse Immunotherapy for the Treatment of Genitourinary Malignancies

    Published 11/1/2021

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Genitourinary Malignancies, provides an overview of immunotherapy treatment for renal cell carcinoma, urothelial carcinoma, and prostate cancer. Multiple clinical trials dealing with all three cancer types are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for these cancers.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available: November 1, 2021 - November 1, 2022

     

    Estimated time to complete activity:  30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for renal cell carcinoma, urothelial carcinoma, and prostate cancer.
    • Identify clinical trials relating to these cancers, as well as the FDA-approved treatments for each.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Mehmet Asim Bilen, MD

    Genitourinary Medical Oncologist

    Emory University, Atlanta, GA

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Mehmet Asim Bilen, MD - Consulting Fees: Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, and Sanofi; Grants to the institution - Xencor, Bayer, Bristol-Myers Squibb, Genetech/Roche, Seattle Genetics, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 11/1/2021 through 11/1/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.2 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-3074-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Genitourinary Malignancies
    Collapse Immunotherapy for the Treatment of Gastrointestinal Cancers

    Published: 3/1/2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Gastrointestinal Cancers, provides an overview of immunotherapy treatment for hepatocellular, colorectal, and other gastrointestinal malignancies. Multiple clinical trials dealing with these types of cancer are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for gastrointestinal cancers.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  March 1, 2022 - March 1, 2023

    Estimated time to complete activity:  30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for gastrointestinal cancer.
    • Identify various studies that are stil ongoing as well as completed clinical trials which have resulted in approvals by disease state.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Aiwu Ruth He, MD, PhD

    Associate Professor of Medicine, Medstar Georgetown University Hospital

    Georgetown University

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Aiwu Ruth He, MD, PhD:  Consulting Fees: Merck, Bayer, BMS, Aztrazeneca; Fees for Non-CE Service: Eisai, BMS, Exelixis; Contracted Research: Merck, Genentech

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number  - JA4008162-9999-22-082-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Gastrointestinal Cancers
    Collapse Immunotherapy for the Treatment of the Head and Neck Cancer

    Published 3/15/2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program.  Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Head and Neck Cancer, provides an overview of immunotherapy treatment for head and neck cancers. Multiple clinical trials dealing with head and neck cancers are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for head and neck cancers.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  March 15, 2022 - March 15, 2023

     

    Estimated time to complete activity:  30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for head and neck cancer.
    • Identify immune-related toxicities related to head and neck cancer immunotherapy agents, and also used in combination with chemotherapy agents.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Anshu Giri, MD, MS

    Assistant Professor, Department of Hematology/Oncology

    Fox Chase Cancer Center

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Anshu Giri, MD, MS: Nothing to disclose. 

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 3/15/2022 through 03/15/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.4 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-22-109-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of the Head and Neck Cancer
    Collapse Immunotherapy for the Treatment of Microsatellite Instability or Tumor Mutation Burden - High Cancers

    Published 10/07/2021

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Microsatellite Instability or Tumor Mutational Burden-High Cancers, provides an overview of immunotherapy treatment for cancers with these characteristics. This course will help the learner understand what microsatellite instability (MSI)  and tumor mutational burden (TMB) terms mean, what meaures can be performed to identify MSI/TMB, various FDA-approved regimens for cancers that are MSI/TMB-high, and provide current clinical trial information.    Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy for the treatment of cancers with high or low microsatellite instability and/or tumor mutational burden.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available: October 7, 2021 - October 7, 2022

     

    Estimated time to complete activity: 30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Define the meaning of microsatellite instability and tumor mutational burden.
    • Identify the methods used to measure MSI or TMB.
    • Describe the rationale for common approaches to cancer immunotherapy with MSI/TMB measures identified.

     

    Faculty
    Dung Le, MD

    Associate Professor, GI Medical Oncology

    Sydney Kimmel Cancer Care Center, Johns Hopkins University

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Dung Le, MD: Consulting Fees: Merck, Bristol Myers Squibb, Janssen, Nouscom.   Contracted Research: Merck, Bristol Myers Squibb, Aduro Biotech, Medivir, Curegenix, Nouscom

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 10/7/2021 through 10/7/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-3027-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Microsatellite Instability or Tumor Mutation Burden - High Cancers
    Collapse Toxicity Management

    Published March 1, 2022

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    In this course, Toxicity Management, learners will be given information on the incidence, onset, severity and grading of immune-related toxicities; as well as immune-related adverse events with immune checkpoint inhibitors.  Dr. Jarushka Naidoo will also discuss cellular therapy adverse events and their management and discuss immunotherapy in special patient populations.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available: March , 2022 - March 1, 2023

     

    Estimated time to complete activity: 45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify immune-related toxicities by grade, onset, and incidence.
    • Identify immune-related adverse events resulting from immune checkpoint inhibitors.
    • Describe the adverse events and management of cellular therapies.
    • Describe the precautions needed when immunotherapy is provided to special patient populations.

     

    Faculty
    Jarushka Naidoo, MBBCh

    Assistant Professor of Oncology and Attending Physician

    Sydney Kimmel Cancer Center, Johns Hopkins University

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Jarushka Naidoo, MBBCh: Consulting Fees: Astrazeneca, Bristol Meyers-Squibb, Roche/Genetech.  Non-CME Services: Merck,  Bristol Myers-Squibb, Astrazeneca.  Contracted Research: Astrazeneca, Merck.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 3/1/2022 through 03/01/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162 - 9999-22-083-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: July 01, 2021

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Toxicity Management
    Collapse Immunotherapy for the Treatment of Hematologic Malignancies

    Published 6/25/2021

     

    Course description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Hematologic Malignancies, provides an overview of the various treatment approaches to hematologic malignancies. This module will provide an overview of the major immunotherapies in development, FDA-approved treatments as well as the side effects associated with those treatments, and current clinical trials.  Learners will have an opportunity to apply what they've learned through two case studies.  By the end of the course, participants will be better able to implement immunotherapy for the treatment of hematologic malignancies.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  June 25, 2021 - June 25, 2022

     

    Estimated time to complete activity: 45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Discuss the purpose of immune checkpoint inihibitors, as well as identify which have been approved by the FDA.
    • Recognize antibody-drug conjugates (ADCs), which have been FDA-approved, and appropriate malignancies for which ADCs would be effective.
    • Identify bispecific antigens' role in immunotherapy.
    • Describe cellular therapies, including CAR T cell therapies and the side effects, current FDA approvals, and clinical trials in development.

     

    Faculty
    Hongtao Liu, MD, PhD

    Associate Professor of Medicine

    Co-Director, Combined Apheresis Unit

    Medical Director, Clinical Cellular Labratory Section of Hematology/Oncology

    Department of Medicine, University of Chicago

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Hongtao Liu, MD, PhD - Consulting Fees: Agios Pharmaceuticals; BeiGene, NGM Biopharmarmaceuticals. Contracted Research: BMS; Karyopharm, Miltenyi.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 6/25/2021 through 6/25/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2839-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: June 23, 2021
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Hematologic Malignancies
    Collapse What

    Published July 28, 2021

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, What's Next in Cancer Immunotherapy, provides an overview of several publications researching the conditions and stresses of the tumor microenvironment, as well as discussing some of the major factors impacting those providing and receiving immunotherapy treatments.  At the end of this course, participants have a better understanding not only of stress sensor impacting tumor cell growth, but also some of the major hurdles affecting immunotherapy's progression. 

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  July 28, 2021 - July 28, 2022

     

    Estimated time to complete activity: 45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify three stress sensors impacting the endoplasmic reticulum.
    • Explain why targeting the cell's response to these stress sensors may be the key to immunotherapy treatments.
    • Identify several of the major hurdles impacting current and future cancer immunotherapy.

     

    Faculty
    Jessica Thaxton, PhD, MsCR

    Assistant Professor

    Hollings Cancer Center, Medical University of South Carolina

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Jessica Thaxton, PhD, MsCR: Research grants TEVA Pharmaceuticals

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 7/28/2021 through 7/28/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2862-H01-P)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: May 25, 2021
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO What
    Collapse Immunotherapy for the Treatment of Lung Cancer

    Originial publish date: May 21, 2021

    PLEASE NOTE: This course is no longer available for CE credit.  To see a list of courses available for credit, please click HERE for a complete listing.

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Lung Cancer, provides an overview of immunotherapy treatment for lung cancer. Multiple clinical trials dealing with both non-small cell lung cancer and small cell lung cancer are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for lung cancers.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Continuing Education Information

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available:  May 21, 2021 - May 21, 2022

     

    Estimated time to complete activity: 45 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for lung cancer.
    • Identify immune-related toxicities related to lung cancer immunotherapy agents.
    • Describe the rationale for common approaches to cancer immunotherapy.

     

    Faculty
    Jennifer Carlisle, MD

    Assistant Professor

    Emory University

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

    Jennifer Carlisle, MD: Nothing to disclose.

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

     

    Method of Participation and Request for Credit
    During the period 5/21/2021 through 5/21/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.4 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2718-H01)

    Type of Activity: Knowledge


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

    Original Course Date: May 21, 2021

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Lung Cancer
    Collapse Immunotherapy for the Treatment of Breast and Gynecologic Cancers

    Original publish date: May 13, 2021.  Please note: this course is no longer available for CE credits. 

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer's (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at https://www.sitcancer.org/education/aci/online.

     

    This course, Immunotherapy for the Treatment of Breast and Gynecologic Cancers, provides an overview of the currently-approved treatments used to treat both breast and gynecologic cancers, as well as a synopsis of future potential applications of immunotherapy for these cancers.  Several clinical trials and two case studies are discussed, allowing the learner to better understand the current use of immunotherapy as well as how clinical trials are leading the way to additional use of immunotherapy for both types of cancer.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

     

     

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Credit Available: May 13, 2021 - May 13, 2022

     

    Estimated time to complete activity: 30 minutes

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the early stage application of breast and gynecologic cancer immunotherapy treatment in relation to standard-of-care therapies
    • Select cancer immunotherapy treatment for breast and gynecologic cancer and better manage common side effects
    • Describe the rationale for common approaches to cancer immunotherapy

    Faculty
    Megan Kruse, MD

    Associate Staff Physician

    Hematology and Medical Oncology

    Cleveland Clinic

     

    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

     

    The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

     

    Megan Kruse, MD: Consulting Fees: Puma biotechnology, Immunomedics, Eisai, Seattle Genetics, Lilly Oncology, Novartis Oncology.   Contracted Research: Tempus.

     

    The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 
     

    Method of Participation and Request for Credit
    During the period 5/13/2021 through 5/13/2022 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Credit Designation

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2714-H01-P)

    Type of Activity: Knowledge

     


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     

     

    Original Course Date: May 13, 2021

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Breast and Gynecologic Cancers
    Collapse Practical Barriers in Cancer Immunotherapy Treatment

    This course is no longer available for continuing education credit.

     

    Published February 23, 2021

     

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Practical Barriers in Cancer Immunotherapy Treatment, provides a detailed overview of how to overcome barriers to obtaining reimbursement from both Medicare and commercial payers for the use of immunotherapy in cancer treatment.
     

    At the end of this course, participants will be able to identify solutions to overcome both operational and financial barriers to integrating immunotherapy into their practice setting.

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Faculty
    Sigrun Hallmeyer, MD

    Medical Director, Cancer Service Line

    Medical Director, Cancer Survivorship Center

    Advocate Lutheran General Hospital

    Chair, Executive Committee

    Association of Community Cancer Centers, Immuno-Oncology Institute


     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify and implement solutions to overcome operational barriers to implementing cancer immunotherapy in the clinical setting. 
    • Identify and implement solutions to overcome financial barriers to implementing cancer immunotherapy in the clinical setting.

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     


    Continuing Education Information

     

    Credit Available: February 23, 2021 - February 23, 2022

     

    Estimated time to complete activity: 1.25 hours

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-21-2606-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Sigrun Hallmeyer, MD: Consulting Fees: Bristol Myers Squibb; Cardinal Health; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Bristol Myers Squibb

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 



    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: February 23, 2021

    Approved Credit:
  • ACPE: 1.25 hours Contact Hour
  • ANCC: 1.25 hours Contact Hour
  • ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Practical Barriers in Cancer Immunotherapy Treatment
    Collapse Mechanisms of Immune-Related Adverse Events

    Please note: this course is no longer eligible for continuing education credits.

     

    Published December 24, 2020

     

    Course Description

    This interactive course provides an overview of the mechanisms by which cancer immunotherapy may activate immune-related adverse events (irAEs). The foundational knowledge presented in this course is critical to understanding how and why immune-related adverse events occur and how they can be treated.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Faculty
    Pradnya Patil, MD, FACP

    Hematology/Oncology Fellow

    Taussig Cancer Institute, Cleveland Clinic


     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Discuss the mechanisms of peripheral and central immune tolerance.
    • Describe the biological pathways involved in mediating autoimmune reactions.
    • Explain the differences between PD-1 and CTLA-4 pathway-mediated autoimmunity.

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     


    Continuing Education Information

     

    Credit Available: December 24, 2020 - December 24, 2021

     

    Estimated time to complete activity: 0.5 hour

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

      PIM_logo.pngsitc_log_color.png

     

    The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2520-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.  Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Pradnya Patil, MD, FACP: Nothing to disclose

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: December 24, 2020

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Mechanisms of Immune-Related Adverse Events